Cipla Ltd · NSE:CIPLA
Cipla — Investor Presentation (August 2023)
8 slides from Cipla's investor presentation, August 2023
Slide 1: MD & GCEO’s Address
MD & GCEO’s Address Umang Vohra Aug 2023 1
Slide 2: CIPLA – FY23 Performance
CIPLA – FY23 PERFORMANCE We delivered strong performance across our key markets; upward operating profitability trajectory sustained Revenue (YoY Growth) EBITDA Margin R&D Spends2 Global Cipla Global 5% Global 22% ~6% 20% Ex-Covid 11% Adj. margin1 ~23% of Revenue (YoY) Revenue (Ex-Covid) 13% (YoY Gr
Slide 3: Cipla – Standing Strong, Caring for Life
Cipla – Standing Strong, Caring for Life HEALTH EDUCATION PALLIATIVE CARE CARING IS THE FOUNDATION SOUTH AFRICA DISASTER RESPONSE SKILLING Cipla Foundation works across five focus areas of Health, Education, Disaster Response, Skilling and Sustainability in SUSTAINABILITY India and South Africa.
Slide 4: Cipla- Driving growth, delivering pioneering and innovative healthcare solutions
Cipla- Driving growth, delivering pioneering and innovative healthcare solutions Lung Leadership 1 AMR 2 Build capabilities and drive stewardship activities to counter Become a global lung leader across the care continuum Innovative Drug device play - the global threat of Anti-microbial resistance (
Slide 5: CIPLA – FY23 ESG Progress
CIPLA – FY23 ESG Progress Recognition for high corporate governance & Continued Progress on ESG Goals sustainability practices KPMG India ESG Excellence Awards, 2023 ICSI Awards ‘Business Responsibility and Sustainability’ Awards, 2022 & ‘Certificate of Recognition’ for excellence in Corporate Gover
Slide 6: CIPLA – Remediation at our sites continues
CIPLA – Remediation at our sites continues Goa Indore ➢ Expect re-inspection in the second half of this ➢ Indore Inspection classification : OAI financial year. ➢ Gx Advair is being de-risked to an in-house ➢ Successful inspection by MHRA in Jun facility. Expect to market in 12 Months timeframe, a p
Slide 7: Cipla of the Future
Cipla of the Future Pioneering, Innovative and Firmly rooted in Care Our Purpose, our true North Innovation key driver for future Sustainable Future Biosimilars mRNA Global Digital Wellness outreach Franchise Respiratory Leaders: Drug device + Bio Drugs Diagnostics Industry 4.0 A Momentous Year Cipl
Slide 8: Thank You!
Thank You! 8